DOCSLIB.ORG

Clinical Disease Presentation and ECG Characteristics of LMNA Mutation Carriers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Disease Presentation and ECG Characteristics of LMNA Mutation Carriers Heart failure and cardiomyopathies Open Heart: first published as 10.1136/openhrt-2016-000474 on 9 January 2017. Downloaded from Clinical disease presentation and ECG characteristics of LMNA mutation carriers Laura Ollila,1 Kjell Nikus,2 Miia Holmström,3 Mikko Jalanko,1 Raija Jurkko,1 Maija Kaartinen,1 Juha Koskenvuo,4,5 Johanna Kuusisto,6 Satu Kärkkäinen,7 Eeva Palojoki,1 Eeva Reissell,8 Päivi Piirilä,9 Tiina Heliö1 To cite: Ollila L, Nikus K, ABSTRACT et al KEY QUESTIONS Holmström M, . Clinical Objective: Mutations in the LMNA gene encoding disease presentation lamins A and C of the nuclear lamina are a frequent and ECG characteristics of What is already known about this subject? cause of cardiomyopathy accounting for 5–8% of LMNA mutation carriers. ▸ Although ventricular dilation and dysfunction Open Heart 2017;4:e000474. familial dilated cardiomyopathy (DCM). Our aim was to may remain less severe than in other forms of doi:10.1136/openhrt-2016- study disease onset, presentation and progression dilated cardiomyopathy, the penetrance of cardi- 000474 among LMNA mutation carriers. olaminopathy mutations is almost complete Methods: Clinical follow-up data from 27 LMNA often resulting in serious arrhythmias or heart mutation carriers and 78 patients with idiopathic DCM failure. Cardiomyopathy-causing LMNA muta- Received 14 May 2016 without an LMNA mutation were collected. In addition, tions often present with typical ECG abnormal- Revised 3 September 2016 ECG data were collected and analysed systematically ities, such as atrioventricular block and atrial or Accepted 1 November 2016 from 20 healthy controls. ventricular arrhythmias. Results: Kaplan-Meier analysis revealed no difference in event-free survival (death, heart transplant, What does this study add? ▸ LMNA resuscitation and appropriate implantable cardioverter- We report that most mutation carriers defibrillator therapy included as events) between LMNA present with non-sustained ventricular tachycar- mutation carriers and DCM controls (p=0.5). LMNA dia (NSVT) in close follow-up. In addition, we LMNA mutation carriers presented with atrial fibrillation at a reaffirm that male mutation carriers have an earlier disease onset than females. We younger age than the DCM controls (47 vs 57 years, http://openheart.bmj.com/ LMNA p=0.003). Male LMNA mutation carriers presented with suggest that mutation carriers likely clinical manifestations roughly a decade earlier than benefit from close follow-up. We also present a females. In close follow-up non-sustained ventricular new ECG entity, septal remodelling, present in LMNA tachycardia was detected in 78% of LMNA mutation most mutation carriers and suggesting carriers. ECG signs of septal remodelling were present that the pathological process leading to cardiola- in 81% of the LMNA mutation carriers, 21% of the minopathy typically affects the myocardial DCM controls and none of the healthy controls giving septum. a high sensitivity and specificity for the standard ECG How might this impact on clinical practice? in distinguishing LMNA mutation carriers from patients ▸ The detection of septal remodelling in standard on September 28, 2021 by guest. Protected copyright. with DCM and healthy controls. ECG should lead to an echocardiogram and Conclusions: Male LMNA mutation carriers present thorough enquiry of cardiac family history. clinical manifestations at a younger age than females. ▸ Even asymptomatic LMNA mutation carriers ECG septal remodelling appears to distinguish LMNA need follow-up to detect atrial fibrillation and mutation carriers from healthy controls and patients NSVTs. with DCM without LMNA mutations. consequently implantable cardioverter- defibrillator (ICD) implantation has been INTRODUCTION suggested as primary prophylaxis for all LMNA mutations are prevalent in familial LMNA mutation carriers, or after further risk dilated cardiomyopathy (DCM), accounting assessment.45Cardiolaminopathy often for about 5–8% of the cases.1 The typical follows an age-dependent disease progression For numbered affiliations see LMNA end of article. early manifestations of mutations are in which the ECG and rhythm abnormalities ECG abnormalities including flat P wave, tend to precede structural heart disease and Correspondence to atrioventricular block, supraventricular and systolic impairment, which in turn often does 23 fi Dr Laura Ollila; ventricular arrhythmias. LMNA mutations not ful l the echocardiography criteria for [email protected] pose a risk for sudden cardiac death, and DCM due to milder dilation of the left Ollila L, Nikus K, Holmström M, et al. Open Heart 2017;4:e000474. doi:10.1136/openhrt-2016-000474 1 Open Heart Open Heart: first published as 10.1136/openhrt-2016-000474 on 9 January 2017. Downloaded from ventricle or dilation with preserved ejection fraction.36 hospital records. First incidences of atrial fibrillation, Lately LMNA mutations have also been linked to familial non-sustained ventricular tachycardia (NSVT), resuscita- forms of mainly right ventricular disease manifestations tion or appropriate ICD therapy, cardiogenic embolism resembling arrhythmogenic right ventricular and pacemaker/ICD implantations were recorded. cardiomyopathy.78 NSVT was defined as more than three consecutive ven- Structural heart disease can result in general, non- tricular beats in 24-hour Holter or clinical exercise test. localising ECG changes, such as left ventricular hyper- To avoid bias, NSVTs were not recorded in the DCM trophy (LVH), ST depression, widening of the QRS controls due to the less vigorous follow-up of the DCM complex, and P terminal force.910On the other hand, control group compared with the LMNA mutation ECG changes in leads overlying affected regions can carrier group. Owing to the small number of major clin- reflect regional disease processes. For instance, narrow ical events in the LMNA mutation carrier group, a com- and deep q waves are typical for localised wall thickening posite end point of resuscitation, appropriate ICD in hypertrophic cardiomyopathy.11 therapy, death and heart transplant was used. In LMNA Late gadolinium enhancement (LGE) in cardiac MRI mutation carriers with available CMR data, the presence (CMR) is considered an effective tool in showing myo- of the ECG parameter septal remodelling was compared cardial scarring.12 In LMNA mutation carriers LGE has with CMR findings from a previous article;13 the CMR been mainly seen in the basal or mid-ventricular septum methods were presented earlier. suggesting a possible localised disease process.13 14 The study patients gave written informed consent. The The aim of this study was to assess disease presenta- study was approved by the Ethics Committee of the tion, progression and clinical outcome in symptomatic Helsinki University Central Hospital (Decision number: and asymptomatic LMNA mutation carriers. Dnro 322/E5/03, Research permit number: T1010K0019). ECG analyses METHODS One standard 12-lead ECG recorded by 50 mm/s speed of Patients and controls each LMNA mutation carrier, DCM control and healthy fi This longitudinal retrospective study included all identi ed control was analysed in a systematic manner manually by LMNA adult mutation carriers from Helsinki and Kuopio one investigator (KN) blinded to the clinical data. The University Hospitals willing to participate in a follow-up ECG recording was from the time of study recruitment. LMNA study. Twenty-seven mutation carriers were recruited The age at the time of ECG recording was 42 years for all to the study between 1999 and 2010. The mutation car- LMNA mutation carriers; 49 years for those with DCM fi LMNA riers, each harbouring one of ve mutations (LMNA-DCM subgroup), and 37 years for those without. ((NM_170707.3 (LMNA), c427T>C, p.(Ser143Pro) in The following definitions were used in the ECG analyses: http://openheart.bmj.com/ exon 2; c.394G>C, p.(Ala132Pro) in exon 2; c.568C>T, first-degree atrioventricular block was defined as PR inter- p.(Arg190Trp) in exon 3; c. 1493delG, p.(Ala499Leufs*49) val >200 ms,18 P terminal force as negative portion of in exon 9; c. 1085delT, p.(Leu363Trpfs*117) in exon 6) the P wave in lead V1≥0.4 mm/s,19 flat P wave as P-wave were either probands or their family members from nine amplitude <1 mm in lead II, and broad P wave as ≥120 ms fi 15 16 families identi ed in two previous studies. Clinical in lead II20 LVH was defined according to the LMNA follow-up data from the mutation carriers and DCM Sokolow-Lyon criteria,21 or Cornell voltage duration controls were collected up to 31 December 2014. Control product (QRS-duration (ms)×(RaVL in mm+SV3 in mm patients (n=78) with idiopathic DCM were collected from a with 6 mm added for women) ≥2440),22 23 for ST segment patient database retrospectively. Probands with DCM, diag- depression we used ≥0.5 mm if the pattern was horizontal on September 28, 2021 by guest. Protected copyright. nosed and recruited before 2010 were included as DCM or descending, and ≥1mmifascendingin ≥2 adjacent controls; patients recruited after possible heart transplant- leads measured at the J point+60 ms,24 for T-wave inversion ation, were excluded to minimise possible collection bias. ≥1mmin≥2 adjacent leads, except for leads aVR and V1 Only probands who have been tested for cardiomyopathy- was used.25 For fragmented QRS in ≥2 adjacent leads we causing mutations using OsSeq, a next-generation- used the definitions by Das et al.26 Septal fragmentation sequencing method, as described before were included to was considered present if there was QRS fragmentation in LMNA ensure that there were no mutation carriers among ≥2 septal leads (V1–V3). Non-specific intraventricular con- 17 the DCM controls. duction defect was defined as QRS duration ≥120 ms not Concerning the ECG abnormalities, the study patients fulfilling criteria for right or left bundle branch block. were also compared with an available cohort of 20 (7 Owing to the high proportion of implanted pacemakers, men, 13 women) healthy controls. we used anamnestic data of AV block in addition to the findings in the ECG used for analysis.
Load more

Recommended publications
  • Emery-Dreifuss Muscular Dystrophy: the Most Recognizable Laminopathy
    Review paper Emery-Dreifuss muscular dystrophy: the most recognizable laminopathy Agnieszka Madej-Pilarczyk, Andrzej Kochański Neuromuscular Unit, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland The authors dedicate this review to Prof. Irena Hausmanowa-Petrusewicz. Folia Neuropathol 2016; 54 (1): 1-8 DOI: 10.5114/fn.2016.58910 Abstract Emery-Dreifuss muscular dystrophy (EDMD), a rare inherited disease, is characterized clinically by humero-peroneal muscle atrophy and weakness, multijoint contractures, spine rigidity and cardiac insufficiency with conduction defects. There are at least six types of EDMD known so far, of which five have been associated with mutations in genes encoding nuclear proteins. The majority of the EDMD cases described so far are of the emerinopathy (EDMD1) kind, with a recessive X-linked mode of inheritance, or else laminopathy (EDMD2), with an autosomal dominant mode of inheritance. In the work described here, the authors have sought to describe the history by which EDMD came to be distinguished as a separate entity, as well as the clinical and genetic characteristics of the disease, the pathophysiolo- gy of lamin-related muscular diseases and, finally, therapeutic issues, prevention and ethical aspects. Key words: Emery-Dreifuss muscular dystrophy, emerin, lamin A/C, laminopathy, LMNA gene. embryo nic development [14,35]. Lamin A/C plays the Introduction role of a structural integrator in a cell nucleus, ensur- Laminopathies fall within a group of rare diseas- ing the maintenance of the latter’s shape, as well as es connected with structural/functional defects of its mechanical endurance (mechanotransduction). the proteins making up the nuclear envelope (which It takes part in regulation of the cell-division cycle, is composed of inner and outer nuclear membranes).
    [Show full text]
  • Three New Cases of Dilated Cardiomyopathy Caused by Mutations in LMNA Gene
    Acta Myologica • 2017; XXXVI: p. 207-212 Three new cases of dilated cardiomyopathy caused by mutations in LMNA gene Larysa N. Sivitskaya1, Nina G. Danilenko1, Tatiyana G. Vaikhanskaya2, Tatsiyana V. Kurushka2 and Oleg G. Davydenko1 1 Institute of Genetics and Cytology, National Academy of Sciences of Belarus, Minsk, Belarus; 2 Republican Scientific and Practical Center of Cardiology, Minsk, Belarus Three cases of delated cardiomyopathy (DCM) with conduc- Mutations in LMNA affect lamins’ dimerization and as- tion defects (OMIM 115200), limb girdle muscular dystrophy sembly (1, 2). It apparently leads to nuclear stability loss 1B (OMIM 159001) and autosomal dominant Emery-Dreifuss and inability to perform functions in its entirety. The muscular dystrophy 2 (OMIM 181350), all associated with dif- ferent LMNA mutations are presented. Three heterozygous mutations in LMNA lead to at least 10 clinically distinct missense mutations were identified in unrelated patients – p. phenotypes, termed laminopathies, affecting different W520R (c.1558T > C), p.T528R (с.1583С > G) and p.R190P tissues including cardiac and skeletal muscle, cutane- (c.569G > C). We consider these variants as pathogenic, lead- ous, nervous and adipose tissue. There is no explicit ing to isolated DCM with conduction defects or syndromic relation between syndrome development and mutation DCM forms with limb-girdle muscular dystrophy and Emery- domain localization. A number of hot spots were de- Dreifuss muscular dystrophy. The mutations were not detected in the ethnically matched control group and publicly available scribed in LMNA, but the mutations common for lami- population databases. Their de novo occurrence led to the de- nopathies were not found.
    [Show full text]
  • Genetic Mutations and Mechanisms in Dilated Cardiomyopathy
    Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, … , Jessica R. Golbus, Megan J. Puckelwartz J Clin Invest. 2013;123(1):19-26. https://doi.org/10.1172/JCI62862. Review Series Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of congestive heart failure. In hypertrophic cardiomyopathy (HCM), cardiac output is limited by the thickened myocardium through impaired filling and outflow. Mutations in the genes encoding the thick filament components myosin heavy chain and myosin binding protein C (MYH7 and MYBPC3) together explain 75% of inherited HCMs, leading to the observation that HCM is a disease of the sarcomere. Many mutations are “private” or rare variants, often unique to families. In contrast, dilated cardiomyopathy (DCM) is far more genetically heterogeneous, with mutations in genes encoding cytoskeletal, nucleoskeletal, mitochondrial, and calcium-handling proteins. DCM is characterized by enlarged ventricular dimensions and impaired systolic and diastolic function. Private mutations account for most DCMs, with few hotspots or recurring mutations. More than 50 single genes are linked to inherited DCM, including many genes that also link to HCM. Relatively few clinical clues guide the diagnosis of inherited DCM, but emerging evidence supports the use of genetic testing to identify those patients at risk for faster disease progression, congestive heart failure, and arrhythmia. Find the latest version: https://jci.me/62862/pdf Review series Genetic mutations and mechanisms in dilated cardiomyopathy Elizabeth M. McNally, Jessica R. Golbus, and Megan J. Puckelwartz Department of Human Genetics, University of Chicago, Chicago, Illinois, USA. Genetic mutations account for a significant percentage of cardiomyopathies, which are a leading cause of conges- tive heart failure.
    [Show full text]
  • Deciphering Nuclear Mechanobiology in Laminopathy
    cells Review Deciphering Nuclear Mechanobiology in Laminopathy Jungwon Hah and Dong-Hwee Kim * KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-3290-4615 Received: 29 January 2019; Accepted: 5 March 2019; Published: 11 March 2019 Abstract: Extracellular mechanical stimuli are translated into biochemical signals inside the cell via mechanotransduction. The nucleus plays a critical role in mechanoregulation, which encompasses mechanosensing and mechanotransduction. The nuclear lamina underlying the inner nuclear membrane not only maintains the structural integrity, but also connects the cytoskeleton to the nuclear envelope. Lamin mutations, therefore, dysregulate the nuclear response, resulting in abnormal mechanoregulations, and ultimately, disease progression. Impaired mechanoregulations even induce malfunction in nuclear positioning, cell migration, mechanosensation, as well as differentiation. To know how to overcome laminopathies, we need to understand the mechanisms of laminopathies in a mechanobiological way. Recently, emerging studies have demonstrated the varying defects from lamin mutation in cellular homeostasis within mechanical surroundings. Therefore, this review summarizes recent findings highlighting the role of lamins, the architecture of nuclear lamina, and their disease relevance in the context of nuclear mechanobiology. We will also provide an overview of the differentiation of cellular mechanics in laminopathy. Keywords: lamin; laminopathy; cytoskeleton; nucleus 1. Introduction Mechanical stimuli are the key to controlling numerous biological processes, including proliferation, differentiation, and migration [1–3]. Integrin mediates the transduction of forces from the external microenvironment to the intracellular cytoskeleton, and the nucleo-cytoskeletal molecular connections transmit the forces to the intranuclear chromosomal organizations [4,5].
    [Show full text]
  • Genetic Determinants Underlying Rare Diseases Identified Using Next-Generation Sequencing Technologies
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 8-2-2018 1:30 PM Genetic determinants underlying rare diseases identified using next-generation sequencing technologies Rosettia Ho The University of Western Ontario Supervisor Hegele, Robert A. The University of Western Ontario Graduate Program in Biochemistry A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Science © Rosettia Ho 2018 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Medical Genetics Commons Recommended Citation Ho, Rosettia, "Genetic determinants underlying rare diseases identified using next-generation sequencing technologies" (2018). Electronic Thesis and Dissertation Repository. 5497. https://ir.lib.uwo.ca/etd/5497 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Rare disorders affect less than one in 2000 individuals, placing a huge burden on individuals, families and the health care system. Gene discovery is the starting point in understanding the molecular mechanisms underlying these diseases. The advent of next- generation sequencing has accelerated discovery of disease-causing genetic variants and is showing numerous benefits for research and medicine. I describe the application of next-generation sequencing, namely LipidSeq™ ‒ a targeted resequencing panel for the identification of dyslipidemia-associated variants ‒ and whole-exome sequencing, to identify genetic determinants of several rare diseases. Utilization of next-generation sequencing plus associated bioinformatics led to the discovery of disease-associated variants for 71 patients with lipodystrophy, two with early-onset obesity, and families with brachydactyly, cerebral atrophy, microcephaly-ichthyosis, and widow’s peak syndrome.
    [Show full text]
  • Lamin A/C Cardiomyopathy: Implications for Treatment
    Current Cardiology Reports (2019) 21:160 https://doi.org/10.1007/s11886-019-1224-7 MYOCARDIAL DISEASE (A ABBATE AND G SINAGRA, SECTION EDITORS) Lamin A/C Cardiomyopathy: Implications for Treatment Suet Nee Chen1 & Orfeo Sbaizero1,2 & Matthew R. G. Taylor1 & Luisa Mestroni1 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review The purpose of this review is to provide an update on lamin A/C (LMNA)-related cardiomyopathy and discuss the current recommendations and progress in the management of this disease. LMNA-related cardiomyopathy, an inherited autosomal dominant disease, is one of the most common causes of dilated cardiomyopathy and is characterized by steady progression toward heart failure and high risks of arrhythmias and sudden cardiac death. Recent Findings We discuss recent advances in the understanding of the molecular mechanisms of the disease including altered cell biomechanics, which may represent novel therapeutic targets to advance the current management approach, which relies on standard heart failure recommendations. Future therapeutic approaches include repurposed molecularly directed drugs, siRNA- based gene silencing, and genome editing. Summary LMNA-related cardiomyopathy is the focus of active in vitro and in vivo research, which is expected to generate novel biomarkers and identify new therapeutic targets. LMNA-related cardiomyopathy trials are currently underway. Keywords Lamin A/C gene . Laminopathy . Heart failure . Arrhythmias . Mechanotransduction . P53 . CRISPR–Cas9 therapy Introduction functions, including maintaining nuclear structural integrity, regulating gene expression, mechanosensing, and Mutations in the lamin A/C gene (LMNA)causelaminopathies, mechanotransduction through the lamina-associated proteins a heterogeneous group of inherited disorders including muscu- [6–11].
    [Show full text]
  • Hippocampal LMNA Gene Expression Is Increased in Late-Stage Alzheimer’S Disease
    International Journal of Molecular Sciences Article Hippocampal LMNA Gene Expression is Increased in Late-Stage Alzheimer’s Disease Iván Méndez-López 1,2,*,†, Idoia Blanco-Luquin 1,†, Javier Sánchez-Ruiz de Gordoa 1,3, Amaya Urdánoz-Casado 1, Miren Roldán 1, Blanca Acha 1, Carmen Echavarri 1,4, Victoria Zelaya 5, Ivonne Jericó 3 and Maite Mendioroz 1,3,* 1 Neuroepigenetics Laboratory-Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra (UPNA), IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra 31008, Spain; [email protected] (I.B.-L.); [email protected] (J.S.-R.d.G.); [email protected] (A.U.-C.); [email protected] (M.R.); [email protected] (B.A.); [email protected] (C.E.) 2 Department of Internal Medicine, Hospital García Orcoyen, Estella 31200, Spain 3 Department of Neurology, Complejo Hospitalario de Navarra- IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra 31008, Spain; [email protected] 4 Hospital Psicogeriátrico Josefina Arregui, Alsasua, Navarra 31800, Spain 5 Department of Pathology, Complejo Hospitalario de Navarra- IdiSNA (Navarra Institute for Health Research), Pamplona, Navarra 31008, Spain; [email protected] * Correspondence: [email protected] (I.M.-L.); [email protected] (M.M.); Tel.: +34-848-422677 (I.M.-L.) † These authors contributed equally to this work. Received: 30 November 2018; Accepted: 14 February 2019; Published: 18 February 2019 Abstract: Lamins are fibrillary proteins that are crucial in maintaining nuclear shape and function. Recently, B-type lamin dysfunction has been linked to tauopathies. However, the role of A-type lamin in neurodegeneration is still obscure.
    [Show full text]
  • Atrial Fibrillation (ATRIA) Study
    European Journal of Human Genetics (2014) 22, 297–306 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg REVIEW Atrial fibrillation: the role of common and rare genetic variants Morten S Olesen*,1,2,4, Morten W Nielsen1,2,4, Stig Haunsø1,2,3 and Jesper H Svendsen1,2,3 Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting 1–2% of the general population. A number of studies have demonstrated that AF, and in particular lone AF, has a substantial genetic component. Monogenic mutations in lone and familial AF, although rare, have been recognized for many years. Presently, mutations in 25 genes have been associated with AF. However, the complexity of monogenic AF is illustrated by the recent finding that both gain- and loss-of-function mutations in the same gene can cause AF. Genome-wide association studies (GWAS) have indicated that common single-nucleotide polymorphisms (SNPs) have a role in the development of AF. Following the first GWAS discovering the association between PITX2 and AF, several new GWAS reports have identified SNPs associated with susceptibility of AF. To date, nine SNPs have been associated with AF. The exact biological pathways involving these SNPs and the development of AF are now starting to be elucidated. Since the first GWAS, the number of papers concerning the genetic basis of AF has increased drastically and the majority of these papers are for the first time included in a review. In this review, we discuss the genetic basis of AF and the role of both common and rare genetic variants in the susceptibility of developing AF.
    [Show full text]
  • Irreversible Modifications of Chromatin and the Nuclear Lamina: a Review Inside the Nuclear Origin of Alzheimer's Disease
    Revista Mexicana de Neurociencia REVIEW ARTICLE Irreversible modifications of chromatin and the nuclear lamina: A review inside the nuclear origin of Alzheimer’s disease Laura Gil1¶, Gabriela Capdeville2*¶, Ildefonso Rodríguez-Leyva3, Sandra A. Niño4, and María E. Jiménez-Capdeville4 1Departamento de Genética, Escuela de Medicina, Universidad “Alfonso X el Sabio”, Madrid, España; 2Escuela de Medicina, Universidad Panamericana, Mexico City; 3Servicio de Neurología, Hospital Central “Ignacio Morones Prieto”, San Luis Potosí; 4Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico ¶These authors contributed equally in this study. Abstract Dementia is a public health problem with an extraordinary increase in recent years. Alzheimer’s disease (AD) is the most common cause of dementia. This disease has been considered a consequence of cytoplasmic and extracellular accumula- tions of Tau protein and β- amyloid, respectively. Nevertheless, a nuclear origin of AD has recently emerged. Both Tau protein and the nuclear lamin protect the nuclear and chromatin organization for proper gene expression throughout neuronal life. Accumulation of DNA damage, mainly as a result of aging, drives post-mitotic neurons to initiate DNA repair by entering the cell cycle. The complexity of the nucleus-cytoskeleton prevents neurons from dividing and condemns them to a state of hyperdiploidy ending in neuronal death, after transiently prolonging their life. In AD, hippocampal neurons survive their fatal fate by triggering an aberrant structural and functional transformation of the nucleus. Lamin A expression and Tau protein transfer to the cytoplasm results in loss of the protector role of nuclear Tau and the subsequent global chromatin disorgani- zation.
    [Show full text]
  • Genetic Disorder
    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Orphanet Report Series Rare Diseases collection January 2013 Disease Registries in Europe www.orpha.net 20102206 Table of contents Methodology 3 List of rare diseases that are covered by the listed registries 4 Summary 13 1- Distribution of registries by country 13 2- Distribution of registries by coverage 14 3- Distribution of registries by affiliation 14 Distribution of registries by country 15 European registries 38 International registries 41 Orphanet Report Series - Disease Registries in Europe - January 2013 2 http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf Methodology Patient registries and databases constitute key instruments to develop clinical research in the field of rare diseases (RD), to improve patient care and healthcare planning. They are the only way to pool data in order to achieve a sufficient sample size for epidemiological and/or clinical research. They are vital to assess the feasibility of clinical trials, to facilitate the planning of appropriate clinical trials and to support the enrolment of patients. Registries of patients treated with orphan drugs are particularly relevant as they allow the gathering of evidence on the effectiveness of the treatment and on its possible side effects, keeping in mind that marketing authorisation is usually granted at a time when evidence is still limited although already somewhat convincing. This report gather the information collected by Orphanet so far, regarding systematic collections of data for a specific disease or a group of diseases. Cancer registries are listed only if they belong to the network RARECARE or focus on a rare form of cancer. The report includes data about EU countries and surrounding countries participating to the Orphanet consortium.
    [Show full text]
  • Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson-Gilford Progeria Syndrome
    bioRxiv preprint doi: https://doi.org/10.1101/790477; this version posted October 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Paradoxical Aortic Stiffening and Subsequent Cardiac Dysfunction in Hutchinson‐Gilford Progeria Syndrome S‐I. Murtada1, Y. Kawamura1, A.W. Caulk1, H. Amadzadeh1, N. Mikush2, K. Zimmerman3, D. Kavanagh3, D. Weiss1, M. Latorre1, Z.W. Zhang4, G.S. Shadel5, D.T. Braddock3, J.D. Humphrey1,6 1Department of Biomedical Engineering Yale University, New Haven, CT, USA 2Translational Research Imaging Center, 3Department of Pathology, 4Section of Cardiovascular Medicine, and 6Vascular Biology and Therapeutics Program Yale School of Medicine, New Haven, CT, USA 5Molecular and Cellular Biology Salk Institute for Biological Studies, La Jolla, CA, USA Address for Correspondence: J.D. Humphrey, Ph.D. Department of Biomedical Engineering Yale University, New Haven, CT 06520 USA +1‐203‐432‐6428 [email protected] Running Title: Aortic Stiffening in late‐stage Progeria Keywords: progeria, aortic stiffness, pulse wave velocity, diastolic dysfunction, allometric scaling, aging 1 bioRxiv preprint doi: https://doi.org/10.1101/790477; this version posted October 2, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SUMMARY Hutchinson‐Gilford Progeria Syndrome (HGPS) is an ultra‐rare disorder with devastating sequelae resulting in early death, presently believed to stem primarily from heart failure secondary to central arterial stiffening. We analyze novel longitudinal cardiovascular data from a mouse model of HGPS (LmnaG609G/G609G) using allometric scaling and advanced computational modelling and show that a late‐stage increase in pulse wave velocity, with associated diastolic dysfunction but preserved systolic function, emerges with a loss of aortic function, independent of sex.
    [Show full text]